<code id='E90EA4B191'></code><style id='E90EA4B191'></style>
      • <acronym id='E90EA4B191'></acronym>
      <center id='E90EA4B191'><center id='E90EA4B191'><tfoot id='E90EA4B191'></tfoot></center><abbr id='E90EA4B191'><dir id='E90EA4B191'><tfoot id='E90EA4B191'></tfoot><noframes id='E90EA4B191'>
      • <optgroup id='E90EA4B191'><strike id='E90EA4B191'><sup id='E90EA4B191'></sup></strike><code id='E90EA4B191'></code></optgroup>
        5. <b id='E90EA4B191'><label id='E90EA4B191'><select id='E90EA4B191'><dt id='E90EA4B191'><span id='E90EA4B191'></span></dt></select></label></b><u id='E90EA4B191'></u>
          <i id='E90EA4B191'><strike id='E90EA4B191'><tt id='E90EA4B191'><pre id='E90EA4B191'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-08-04 10:22:03 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：31
                                  
                                    
          
                                   
          Adobe
          For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.
          Editas Medicine, the winner of that battle in the U.S., will now cash in.
          advertisement
          Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Fetal cell organoids grown from amniotic fluid, study finds
                                
                            
          Next article：  
                                      
                                          Medicare proposal to cover medical devices draws a mixed reaction
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles